Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease

BMJ Open Gastroenterology

Volumn 3, Issue 1, 2016, Pages

  Mehta, Rohini ^a   Otgonsuren, Munkzhul ^a   Younoszai, Zahra ^a   Allawi, Hussain ^a   Raybuck, Bryan ^a   Younossi, Zobair ^a  

^a Betty and Guy Beatty Center for Integrated Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 132; MICRORNA 143; MICRORNA 145; MICRORNA 146A; MICRORNA 211; MICRORNA 241; MICRORNA 30C; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; FEMALE; HUMAN; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; OBESITY; PROTEIN EXPRESSION; TREND STUDY;

EID: 85038970764     PISSN: None     EISSN: 20544774     Source Type: Journal    
DOI: 10.1136/bmjgast-2016-000096     Document Type: Article

References (51)

1. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-33.
2. Chang TC, Mendell JT. microRNAs in vertebrate physiology and human disease. Annu Rev Genomics Hum Genet 2007;8:215-39.
3. Felekkis K, Touvana E, Stefanou Ch, et al. microRNAs: a newly described class of encoded molecules that play a role in health and disease. Hippokratia 2010;14:236-40.
4. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
5. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-8.
6. Matsumura T, Sugimachi K, Iinuma H, et al. Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br J Cancer 2015;113:275-81.
7. Dong H, Li J, Huang L, et al. Serum microRNA profiles serve as novel biomarkers for the diagnosis of Alzheimer's disease. Dis Markers 2015;2015:e625659.
8. Mar-Aguilar F, Mendoza-Ramírez JA, Malagón-Santiago I, et al. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers 2013;34:163-9.
9. Pescador N, Pérez-Barba M, Ibarra JM, et al. Serum circulating microRNA profiling for identification of potential type 2 diabetes and obesity biomarkers. PLoS One 2013;8:e77251.
10. Xu J, Wu C, Che X, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011;50:136-42.
11. Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010;56:1733-41.
12. Turchinovich A, Weiz L, Burwinkel B. Extracellular miRNAs: the mystery of their origin and function. Trends Biochem Sci 2012;37:460-5.
13. Younossi ZM, Reyes MJ, Mishra A, et al. Systematic review with meta-analysis: non-alcoholic steatohepatitis-a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther 2014;39:3-14.
14. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010;103:71-83.
15. Hossain N, Afendy A, Stepanova M, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7:1224-9, 1229.e1-2.
16. Guize L, Pannier B, Thomas F, et al. Recent advances in metabolic syndrome and cardiovascular disease. Arch Cardiovasc Dis 2008;101:577-83.
17. Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007;13:1579-84.
18. Gastaldelli A, Kozakova M, Højlund K, et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009;49:1537-44.
19. Wong VW-S, Wong GL-H, Yip GW-K, et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 2011;60:1721-7.
20. Agaç MT, Korkmaz L, Cavusoglu G, et al. Association between nonalcoholic fatty liver disease and coronary artery disease complexity in patients with acute coronary syndrome: a pilot study. Angiology 2013;64:604-8.
21. Estep M, Armistead D, Hossain N, et al. Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2010;32:487-97.
22. Vacca M, Di Eusanio M, Cariello M, et al. Integrative miRNA and whole-genome analyses of epicardial adipose tissue in patients with coronary atherosclerosis. Cardiovasc Res 2016;109:228-39.
23. McClelland AD, Kantharidis P. MicroRNA in the development of diabetic complications. Clin Sci (Lond) 2014;126:95-110.
24. Ringqvist I, Fisher LD, Mock M, et al. Prognostic value of angiographic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS). J Clin Invest 1983;71:1854-66.
25. Duttagupta R, Jiang R, Gollub J, et al. Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One 2011;6: e20769.
26. Pritchard CC, Kroh E, Wood B, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) 2012;5:492-7.
27. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
28. Tarantino G, Caputi A. JNKs, insulin resistance and inflammation: a possible link between NAFLD and coronary artery disease. World J Gastroenterol 2011;17:3785-94.
29. Nseir W, Shalata A, Marmor A, et al. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci 2011;56:3439-49.
30. Lonardo A, Sookoian S, Pirola CJ, et al. Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism 2016;65:1136-50.
31. Chen T, Li Z, Tu J, et al. MicroRNA-29a regulates pro-inflammatory cytokine secretion and scavenger receptor expression by targeting LPL in oxLDL-stimulated dendritic cells. FEBS Lett 2011;585:657-63.
32. Miyata R, Kakuki T, Nomura K, et al. Poly(I:C) induced microRNA-146a regulates epithelial barrier and secretion of proinflammatory cytokines in human nasal epithelial cells. Eur J Pharmacol 2015;761:375-82.
33. Neppl RL, Wang DZ. The myriad essential roles of microRNAs in cardiovascular homeostasis and disease. Genes Dis 2014;1:18-39.
34. Wanet A, Tacheny A, Arnould T, et al. miR-212/132 expression and functions: within and beyond the neuronal compartment. Nucleic Acids Res 2012;40:4742-53.
35. Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 2013;10:542-52.
36. Shaked I, Meerson A, Wolf Y, et al. MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase. Immunity 2009;31:965-73.
37. Huang Y, Lei Y, Zhang H, et al. MicroRNA regulation of STAT4 protein expression: rapid and sensitive modulation of IL-12 signaling in human natural killer cells. Blood 2011;118:6793-802.
38. Molnár V, Érsek B, Wiener Z, et al. MicroRNA-132 targets HB-EGF upon IgE-mediated activation in murine and human mast cells. Cell Mol Life Sci 2012;69:793-808.
39. Alvarez-Saavedra M, Antoun G, Yanagiya A, et al. miRNA-132 orchestrates chromatin remodeling and translational control of the circadian clock. Hum Mol Genet 2011;20:731-51.
40. Strum JC, Johnson JH, Ward J, et al. MicroRNA 132 regulates nutritional stress-induced chemokine production through repression of SirT1. Mol Endocrinol 2009;23:1876-84.
41. Rangrez AY, Massy ZA, Metzinger-Le Meuth V, et al. miR-143 and miR-145 molecular keys to switch the phenotype of vascular smooth muscle cells. Circ Cardiovasc Genet 2011;4:197-205.
42. Elia L, Quintavalle M, Zhang J, et al. The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ 2009;16:1590-8.
43. Xin M, Small EM, Sutherland LB, et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev 2009;23:2166-78.
44. Ji R, Cheng Y, Yue J, et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of microRNA in vascular neointimal lesion formation. Circ Res 2007;100:1579-88.
45. Hunter MP, Ismail N, Zhang X, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008;3:e3694.
46. Wang K, Zhang S, Weber J, et al. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res 2010;38:7248-59.
47. Ohshima K, Inoue K, Fujiwara A, et al. Let-7 MicroRNA Family Is Selectively Secreted into the Extracellular Environment via Exosomes in a Metastatic Gastric Cancer Cell Line. PLoS ONE 2010;5:e13247.
48. Pigati L, Yaddanapudi SCS, Iyengar R, et al. Selective release of microrna species from normal and malignant mammary epithelial cells. PLoS One 2010;5:e13515.
49. Zhang Y, Liu D, Chen X, et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell 2010;39:133-44.
50. Iguchi H, Kosaka N, Ochiya T. Secretory microRNAs as a versatile communication tool. Commun Integr Biol 2010;3:478-81.
51. Diehl P, Fricke A, Sander L, et al. Microparticles: major transport vehicles for distinct miRNAs in circulation. Cardiovasc Res 2012;93:633-44.